Abstract
Abstract
Objective
In frst-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC), the ORIENT-11 study demonstrated a signifcant progression-free survival and overall survival for sintilimab plus chemotherapy in comparison with chemotherapy alone. But the cost-effectiveness of the two treatment schemes is unclear in China. The objective of the current study was to evaluate the cost efectiveness of sintilimab plus chemotherapy versus Platinum-based chemotherapy for locally advanced or metastatic squamous NSCLC in China.
Methods
We performed an economic evaluation from the perspective of the Chinese healthcare system using a partitioned survival model with three mutually exclusive health states: progression free, post-progression, and death. The circulation cycle of the model was 3 weeks and the study time limit was 10 years. Efficacy data were obtained from the ORIENT-11 clinical trial. Cost and utility values were derived from published studies and online price databases. The primary outcomes of the model were quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). One-way sensitivity analysis and probability sensitivity analysis were used to verify the robustness of the base-case analysis results.
Results
Sintilimab plus chemotherapy provided an additional 0.6 QALYs. The total cost per patient was CNY¥413,273.16 for sintilimab plus chemotherapy and CNY¥280,695.23 for Platinum-based chemotherapy. The ICER for sintilimab plus chemotherapy was CNY¥220,963.22/QALY. Sensitivity analyses found the results to be most sensitive to the cost of pemetrexed and utilities of PF state. In the probabilistic sensitivity analysis, sintilimab was cost-efective in 78.6% of the simulations, assuming a willingness-to-pay threshold (WTP) of CNY¥242,928 per QALY.
Conclusion
Compared with chemotherapy alone, the sintilimab plus chemotherapy is likely to be a cost-effective option as the first-line treatment for locally advanced or metastatic nonsquamous NSCLC in China.
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Liu Z, Li Z, et al. Interpretation on the report of Global Cancer Statistics 2020 [J]. Journal of Multidisciplinary Cancer Management. 2021;7(02):1–14.
2. The National Health Commission. China Health Statistics Yearbook[M].Beijing:Beijing Union Medical College Press,2021:146.
3. Yang Y, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Ma R, Bi M. Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology pRogram by InnovENT anti-PD-1-11). J Thoracic Oncol. 2020;15(10):1636–46.
4. LIU Xinyi, TAN Chongqinga, ZENG Xiaohuib, PENG Liubao, WAN Xiaomin. Introduction of Partitioned Survival Model in Pharmacoeconomics Evaluation and Case Analysis[J].Chin J Mod Appl Pharm,2019,36(24):3090–3093.DOI:https://doi.org/10.13748/j.cnki.issn1007-7693.2019.24.018.
5. Fenghao S, Ye S, Mingjun R, Aixia Ma. Application of survHE package of R in health economics evaluation [J]. China HealthEcon. 2020;39(09):9–14.